Aim. To study serum biomarker profile in patients with coronary artery disease (CAD) and psoriasis and the impact on the incidence of hospitalization for cardiovascular reasons and psoriasis.Material and methods. The study included 90 patients divided into following 3 groups: with psoriasis (n=30), coronary artery disease (CAD) (n=30) and CAD+psoriasis (n=30) in whom serum biomarkers were determined at the beginning of the study (growth stimulation expressed gene 2, N-terminal pro-brain natriuretic peptide (NT-proBNP), interleukin-17 and tumor necrosis factor alpha) and hospitalization rates were monitored over 4 years.Results. There was a significant difference in the concentrations of all biomarkers between the groups (p<0,05), with the maximum values being in the CAD+psoriasis group, except for NT-proBNP. In regression analysis, risk factors for cardiovascular hospitalizations were psoriasis (p=0,049) and increased NT-proBNP concentrations (p<0,001).Conclusion. Comorbidity leads to an increase in the serum concentration of biomarkers, while the risk factors for cardiovascular hospitalization were psoriasis and serum NT-proBNP level.
13 April 2025 in Siberian Journal of Clinical and Experimental Medicine
Psoriasis is a chronic immune-inflammatory dermatological disease that affects not only the skin, but can also cause systemic inflammation, increasing cardiovascular endpoints.Aim: To examine long-term cardiovascular endpoints in patients with coronary heart disease (CHD), psoriasis and their combination in a prospective observational study.Material and Methods. 3 groups of patients with moderate-to-severe psoriasis (n = 30), coronary artery disease (CHD) (n= 32) and psoriasis + coronary artery disease (n= 28) were enrolled in the study. They were observed for 48 months in terms of unfavourable endpoints (exacerbation of psoriasis, cardiac vascular hospitalizations, death, heart attacks and strokes).Results. The CHD group had a higher frequency of diabetes mellitus (DM) (30 vs. 3.6%, p = 0.008) and worse systolic blood pressure (SBP) control (142 (134.0–149.8) vs. 136 (128.0–144.6) mmHg, p = 0.048) compared with the CHD comorbidity group. Cardiovascular mortality was higher in patients with CHD compared with the group with psoriasis (p = 0.027) and CHD with psoriasis (p = 0.040). The rate of cardiovascular hospitalizations did not differ in pairs with CHD versus CHD and exacerbations of psoriasis in the groups with psoriasis and psoriasis with CHD (p > 0.05), but the total rate of both types of hospitalizations was higher in the group of patients with CHD and psoriasis (p = 0.009).Conclusion. In case of comorbidity of psoriasis with CHD, the frequency of cardiovascular hospitalizations and exacerbation of psoriasis increased. CHD reduced the time to the first exacerbation of psoriasis.